



April 28, 2026

Company name: Nippon Soda Co., Ltd.  
Name of representative: Eiji Aga  
Representative Director and President  
(Securities code: 4041; TSE Prime Market)  
Inquiries: Toyonobu Katagishi  
Manager of General Affairs Dept.  
(Telephone: +81-3-6366-1920)

## Acquisition of License for Therapeutic Antibody for Feline Inflammatory Diseases from MabGenesis Inc.

Nippon Soda Co., Ltd. (hereinafter "the Company") is pleased to announce that the Company has acquired a license from MabGenesis Inc. (Head Office: Yokohama, Kanagawa, Japan; CEO: Katsuhiko Shinjo; hereinafter "MabGenesis") for the development and commercialization rights of therapeutic antibodies for feline inflammatory diseases developed by MabGenesis.

### 1. About MabGenesis Inc.

MabGenesis is a startup biopharmaceutical company engaged in the research and development of therapeutic monoclonal antibody drugs. The company possesses the world's highest quality phage display antibody library (MOURA library) and provides high-quality monoclonal antibodies that are difficult to obtain using conventional technologies.

In September 2025, Nippon Soda entered into a collaborative research agreement with MabGenesis for the development of novel monoclonal antibody therapeutics for dogs and cats.

### 2. About the Agreement

Under this agreement, MabGenesis will receive an upfront payment and is entitled to receive milestone payments based on developmental progress as well as sales royalties.

#### **Makoto Kato, Executive Officer and General Manager of Chemical Products Division, Nippon Soda Co., Ltd. Commented:**

The animal health field, where we can leverage our chemical and biochemical knowledge cultivated through agrochemical research and development, represents an important area where we can utilize our strengths. Through our collaboration with MabGenesis, we aim to integrate their innovative technologies with our expertise to achieve early commercialization. MabGenesis's MOURA Library, which provides high-performance monoclonal antibodies that are difficult to obtain with conventional technologies, is innovative, and we will work together with MabGenesis to realize the practical application of veterinary monoclonal antibody therapeutics, utilizing our expertise cultivated over many years.

**Katsuhiko Shinjo, DVM, PhD, Chief Executive Officer of MabGenesis commented:**

We are delighted to have the opportunity to license our fully feline monoclonal antibodies, generated through our proprietary antibody platform technology, to Nippon Soda. We are convinced that Nippon Soda's expertise and strong development capabilities will successfully translate this asset into safe and effective treatments for cats worldwide.

The Company's mission is to create new value through the power of chemistry and increase corporate value by contributing to society. Under this mission, the Company will continue to pursue the creation of new businesses in the animal health field. Through this license acquisition, the Company will advance the development and commercialization of antibody therapeutics for cats, contributing to the resolution of social issues related to animal healthcare.